|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.
|
15737014 |
2005 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.
|
15737014 |
2005 |
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.
|
15737014 |
2005 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.
|
15737014 |
2005 |
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
These inhibitors also show effective inhibition of signaling by T790M-mutant EGFR and killing of NSCLC cells with the T790M mutation.
|
15897464 |
2005 |
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
|
16258541 |
2005 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
|
16258541 |
2005 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
|
16258541 |
2005 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We also identified the TKI drug resistance-associated EGFR T790M mutation in an untreated case of Barrett's esophagus and the corresponding adenocarcinoma.
|
16857803 |
2006 |
|
Barrett Esophagus
|
|
0.010 |
GeneticVariation
|
BEFREE |
We also identified the TKI drug resistance-associated EGFR T790M mutation in an untreated case of Barrett's esophagus and the corresponding adenocarcinoma.
|
16857803 |
2006 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
A secondary mutation, T790M, has been associated with acquired resistance but has not been shown to be sufficient to render EGFR mutant/amplified lung cancers resistant to EGFR inhibitors.
|
16906227 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results indicate that the T790M mutation is sometimes present in a minor population of tumor cells during the development of NSCLC and suggest that the detection of small fractions of T790M mutant alleles may be useful for predicting gefitinib resistance of NSCLCs with sensitive EGFR mutations.
|
16912157 |
2006 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results indicate that the T790M mutation is sometimes present in a minor population of tumor cells during the development of NSCLC and suggest that the detection of small fractions of T790M mutant alleles may be useful for predicting gefitinib resistance of NSCLCs with sensitive EGFR mutations.
|
16912157 |
2006 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
A secondary T790M mutation of EGFR accounted for half the tumors with acquired resistance to gefitinib in Japanese patients.
|
17020982 |
2006 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
|
17085664 |
2006 |
|
Metastatic malignant neoplasm to brain
|
|
0.100 |
GeneticVariation
|
BEFREE |
Seven mutations were T790M and one was a novel D761Y mutation found in a brain metastasis.
|
17085664 |
2006 |
|
Metastatic Malignant Neoplasm in the Viscera
|
|
0.010 |
GeneticVariation
|
BEFREE |
In an autopsy case, the T790M mutation was found in multiple visceral metastases but not in a brain lesion.
|
17085664 |
2006 |
|
Lesion of brain
|
|
0.010 |
GeneticVariation
|
BEFREE |
In an autopsy case, the T790M mutation was found in multiple visceral metastases but not in a brain lesion.
|
17085664 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The gefitinib-resistant, T790M-mutant H1975 NSCLC cell line undergoes prominent growth arrest and apoptosis when treated with the irreversible EGFR inhibitor, CL-387,785.
|
17145885 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The detection of a small fraction of T790M-positive alleles may be useful to predict the clinical course of the gefitinib-treated non-small-cell lung cancer patients.
|
17335935 |
2007 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our observations show that EGFR-T790M provides a proliferative advantage with respect to WT EGFR and suggest that the enhanced kinase activity of this mutant is the basis for rare cases of inherited susceptibility to lung cancer.
|
17510392 |
2007 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our observations show that EGFR-T790M provides a proliferative advantage with respect to WT EGFR and suggest that the enhanced kinase activity of this mutant is the basis for rare cases of inherited susceptibility to lung cancer.
|
17510392 |
2007 |
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our observations show that EGFR-T790M provides a proliferative advantage with respect to WT EGFR and suggest that the enhanced kinase activity of this mutant is the basis for rare cases of inherited susceptibility to lung cancer.
|
17510392 |
2007 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A gefitinib-resistant point mutation (T790M) in exon 20 without gefitinib treatment was detected in 1 AAH and 1 adenocarcinoma.
|
17561305 |
2007 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
While they produce dramatic responses in a subset of patients-primarily those with activating EGFR mutations-remissions are typically limited to several months due to acquired drug resistance, frequently associated with the secondary T790M mutation in EGFR.In this issue of Cancer Cell, Li et al. report that an irreversible EGFR kinase inhibitor, HKI-272, had limited activity in a mouse lung cancer model driven by an EGFR mutant harboring T790M and an activating mutation.
|
17613432 |
2007 |